Key Takeaways
Omeros Corporation (NASDAQ: OMER) reported first-quarter net income of $56.1 million, swinging to a profit on the successful launch of its new drug YARTEMLEA, which treats a rare transplant complication.
"Early demand and uptake were strong, and YARTEMLEA became cash flow positive in the first quarter," Chief Executive Officer Dr. Gregory Demopulos said, adding that he expects the drug to drive company-wide positive cash flow within 18 months.
The new treatment, approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), generated gross revenue of $11.1 million and net revenue of $9.9 million. The company's overall Q1 profit, equivalent to $0.78 per share, was aided by a $73.1 million non-cash gain. Excluding that item, the non-GAAP adjusted net loss was $17.1 million, or $0.24 per share.
The launch is a pivotal moment for Omeros, providing a new revenue stream that validates its commercial strategy. The company is now focused on expanding access to all 175 U.S. transplant centers and securing European approval by mid-year, setting the stage for significant growth.
Omeros said its field force is detailing all 175 transplant centers in the U.S. By the end of the first quarter, 30 unique accounts had placed orders, including six of the top 10 transplant sites. The company noted that hospital formulary progress has been faster than expected, with about 30 percent of the top 80 centers having received P&T committee approval.
On the reimbursement front, Demopulos said all prior authorization requests submitted to commercial payers have been approved. Further supporting access, the U.S. Centers for Medicare & Medicaid Services assigned a permanent J-code for YARTEMLEA, effective July 1, and has recommended the drug for a New Technology Add-on Payment (NTAP).
Omeros ended the quarter with $135.3 million in cash and investments after receiving a $240 million upfront payment from a deal with Novo Nordisk for its investigational MASP-3 inhibitor, zaltenibart. The company used part of its cash to repay the remaining $17.1 million of its 2026 notes. Its only remaining debt is $70.8 million in convertible notes due in 2029. During the quarter, Omeros also repurchased approximately 360,000 shares for $4.2 million.
The successful launch provides Omeros with a crucial new revenue stream and a path to profitability that reduces its reliance on partnerships and capital markets. Investors will watch for the European Medicines Agency's decision on YARTEMLEA around mid-year, which could unlock a second major market.
This article is for informational purposes only and does not constitute investment advice.
